A Phase II, Open-Label Study Of Tomivosertib (eFT508) Added On To Continued Checkpoint Inhibitor Therapy In Patients With Insufficient Response To Single Agent Treatment
2020 American Society of Clinical Oncology (ASCO) Annual Meeting
eFT226, a first in class inhibitor of eIF4A, targets FGFR1/2 and HER2 driven cancers
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019
Physical and Functional Interactions between MNK and mTOR Signaling Regulate the Activation and Differentiation of T Cells
American Association for Cancer Research (AACR) Annual Meeting 2019
A focused CRISPR screen to identify synthetic lethal interactions with the novel eIF4A Inhibitor eFT226 in KRAS driven NSCLC
American Association for Cancer Research (AACR) Annual Meeting 2019
Targeting Hormone Receptor-Dependent Cancers with Potent, Selective and Orally-Available Small Molecule Inhibitors of eIF4E
American Association for Cancer Research (AACR) Annual Meeting 2019
Tomivosertib (eFT508), a Potent and Highly Selective Inhibitor of MNK1 and MNK2, Enhances CAR T Cell Activity Through Modulating T Cell Differentiation
American Association for Cancer Research (AACR) Annual Meeting 2019
Targeting PI3K/mTOR Signaling with Potent, Selective and Orally-Available Small Molecule Inhibitors of eIF4E
AACR Special Conference 2018
Inhibition of MNK by eFT508 reprograms T-cell signaling to promote an anti-tumor immune response
AACR Annual Meeting 2018
eFT508, A Potent and Highly Selective Inhibitor of MNK 1/2, Regulates T Cell Differentiation Promoting an Anti-tumor Immune Response
AACR Annual Meeting 2018
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of eFT508, a Selective, Orally Bioavailable Inhibitor of MNK1 and MNK2, in Patients with Hematological Malignancies
American Society of Hematology (ASH) Annual Meeting 2017
Preclinical Evaluation of eFT226, a Novel, Potent and Selective elF4A Inhibitor with Anti-tumor Activity in B-cell Malignancies
American Society of Hematology (ASH) Annual Meeting 2017
eFT508, A Potent and Highly Selective Inhibitor of MNK 1 and MNK2, is an Activator of Anti-Tumor Immune Response
2017 Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
A Phase 1 Dose Escalation Study of eFT508, an Inhibitor of Mitogen-Activated Protein Kinase-Interacting Serine/Threonine Kinase-1 (MNK-1) and MNK-2 in Patients with Advanced Solid Tumors
2017 American Society of Clinical Oncology (ASCO) Annual Meeting
eFT508, A Potent and Highly Selective Inhibitor of MNK 1/2, Regulates Immune Checkpoint and Cytokine Expression Promoting Anti-tumor Immunity
American Association for Cancer Research (AACR) Annual Meeting 2017
eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)
American Society of Hematology (ASH) Annual Meeting 2015